10-Q: Adicet Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Adicet Bio, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, highlighting progress in its gamma delta T-cell therapy programs and recent regulatory milestones.

Summary

• Adicet Bio is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer.
• The company's lead product candidate, ADI-001, is being developed for autoimmune diseases and relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL).
• ADI-270, another product candidate, is designed to target CD70+ solid tumors and hematological malignancies, with renal cell carcinoma (RCC) as the initial focus.
• In the second quarter of 2024, Adicet initiated research and development activities in China through a series of contractual agreements.
• The company raised approximately $19.3 million through an at-the-market offering in January 2024 and $91.7 million through an underwritten public offering in the same month.
• Adicet reported a net loss of $29.9 million for the three months ended June 30, 2024, and $57.9 million for the six months ended June 30, 2024.
• As of June 30, 2024, Adicet had cash and cash equivalents of $224.1 million, which is expected to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and regulatory approvals, the company continues to incur significant losses and will require additional funding. The risks associated with drug development and the competitive landscape temper the overall outlook.

Positives

• The company has a strong cash position of $224.1 million as of June 30, 2024, which is expected to fund operations for at least the next twelve months.
• Adicet has received FDA clearance for IND applications for both ADI-001 and ADI-270, indicating regulatory progress.
• The company has secured Fast Track Designations for both ADI-001 and ADI-270, which may expedite the regulatory review process.
• Adicet is expanding its clinical development of ADI-001 to include SLE, SSc and AAV patients.
• The company is initiating research and development activities in China, which could provide access to a large patient population.

Negatives

• Adicet has incurred significant net operating losses and negative cash flows from operations, with an accumulated deficit of $438.7 million as of June 30, 2024.
• The company has no products approved for commercial sale and does not expect to generate revenue from product sales in the near future.
• Research and development expenses decreased by $2.5 million for the three months ended June 30, 2024, compared to the same period in 2023, primarily due to a decrease in expenses related to CDMOs and other externally conducted research and development.
• The company has deprioritized enrolling LBCL patients in the GLEAN trial to focus on advancing MCL enrollment.

Risks

• The company's business is highly dependent on the success of ADI-001 and ADI-270.
• Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
• The company may encounter substantial delays in clinical trials.
• The market opportunities for product candidates may be limited.
• The company relies on third-party suppliers and manufacturers, which increases the risk of insufficient quantities of product candidates.
• The company is highly dependent on key personnel.
• The company will need substantial additional financing to develop product candidates.
• The pharmaceutical industry in China is highly regulated and subject to change.
• Global conflicts may increase the likelihood of supply interruptions.
• Failure to achieve and maintain effective internal control over financial reporting could harm the business.
• Termination of the collaboration with Regeneron would materially harm the business.

Future Outlook

The company expects its cash and cash equivalents to be sufficient to fund its operating expenses, capital expenditure requirements, and debt service payments for at least the next twelve months. They plan to initiate a Phase 1 clinical trial for ADI-270 in RCC patients in the fourth quarter of 2024 and share preliminary clinical data in the first half of 2025. They also expect to provide a clinical update from the Phase 1 study in MCL patients in the fourth quarter of 2024.

Management Comments

• Management expects operating losses and negative cash flows to continue for the foreseeable future.
• Management believes that the cash and cash equivalents will be sufficient for the company to continue as a going concern for at least twelve months from the issuance date of the financial statements.

Industry Context

The announcement reflects the ongoing trend in the biotechnology industry towards developing novel cell-based therapies for cancer and autoimmune diseases. The focus on allogeneic gamma delta T-cell therapies positions Adicet in a competitive space with other companies exploring similar approaches, as well as those developing autologous CAR T-cell therapies.

Comparison to Industry Standards

• Adicet's focus on allogeneic gamma delta T-cell therapies is a novel approach compared to the more established autologous CAR T-cell therapies, such as those marketed by Gilead (Yescarta) and Novartis (Kymriah).
• The company's approach aims to address some of the limitations of autologous therapies, such as the time and cost associated with manufacturing patient-specific treatments.
• Fate Therapeutics is another company developing allogeneic cell therapies, including CAR NK and CAR T-cell therapies, and has a collaboration agreement with Johnson & Johnson.
• Adicet's clinical trial plans for ADI-001 in autoimmune diseases and ADI-270 in RCC are in line with industry standards for early-stage clinical development of novel therapies.
• The company's financial position, with $224.1 million in cash and cash equivalents, is relatively strong compared to other early-stage biotechnology companies, but it will need to raise additional capital to fund its ongoing and future clinical trials and commercialization efforts.

Related Party Transactions

• Regeneron owned 883,568 shares of the company's common stock as of June 30, 2024.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial position and the inherent risks of drug development.
• Employees may be affected by the company's financial performance and any potential restructuring or layoffs.
• Patients may benefit from the development of new therapies for autoimmune diseases and cancer, but there are risks associated with clinical trials and the availability of approved products.
• Suppliers and manufacturers may be impacted by the company's financial stability and its ability to secure contracts.

Next Steps

• Initiate a Phase 1 clinical trial for ADI-270 in RCC patients in the fourth quarter of 2024.
• Share preliminary clinical data for ADI-270 in the first half of 2025.
• Provide a clinical update from the Phase 1 study in MCL patients in the fourth quarter of 2024.
• Commence enrollment in Phase 1 clinical trial of ADI-001 in LN in the third quarter of 2024.
• Commence enrollment in Phase 1 clinical trials in SLE, SSc and AAV patients in the second half of 2024.
• Provide preliminary clinical data from Phase 1 clinical trial of ADI-001 in LN, SLE, SSc and AAV in the first half of 2025.

Key Dates

Keywords

gamma delta T cell therapy, allogeneic, ADI-001, ADI-270, autoimmune diseases, cancer, clinical trials, FDA, regulatory approval, biotechnology